Human cytomegalovirus (HCMV) infection is a major cause of morbidity and mortality in allogeneic hematopoietic stem cell (HSCT) transplant recipients. Because of HCMV resistance to currently available drugs, novel drugs are needed for the therapeutic management of HCMV-resistant infections in hematopoietic stem cell transplant patients. Human cytomegalovirus (HCMV), also known as human herpesvirus 5 (HHV-5), belongs to the Herpesviridae family, Betaherpesvirinae subfamily.
Human cytomegalovirus (HCMV) is a common virus, and prevalence of HCMV infection is usually higher in developing countries and in individuals of lower socioeconomic status. HCMV is an important concern in some specific high-risk groups, and its primary infection or reactivation from latency may be critical, especially in immunocompromised patients, including HIV-infected individuals and transplant recipients. The risk…
